Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David D Waters

Showing results (101-110 of 157) with videos related to

Pageof 16
Sort By:
Journal of the American Heart Association|January 24, 2018
Relationship of High-Density Lipoprotein Cholesterol With Renal Function in Patients Treated With AtorvastatinKwok Leung Ong, David D Waters, Rana Fayyad, et al.
Journal of the American College of Cardiology|January 31, 2015
Risk of new-onset diabetes and cardiovascular risk reduction from high-dose statin therapy in pre-diabetics and non-pre-diabetics: an analysis from TNT and IDEALPayal Kohli, David D Waters, Rita Nemr, et al.
Circulation|January 31, 2007
Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) studyKiran K Khush, David D Waters, Vera Bittner, et al.
Circulation|August 2, 2011
Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trialPhilip J Barter, Kerry-Anne Rye, Jean-Claude Tardif, et al.
Atherosclerosis|July 24, 2012
A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: the Lipid Treatment Assessment Project 2Raul D Santos, David D Waters, Lisa Tarasenko, et al.
The American Journal of Cardiology|June 23, 2016
Emerging Cardiovascular Disease Biomarkers and Incident Diabetes Mellitus Risk in Statin-Treated Patients With Coronary Artery Disease (from the Treating to New Targets [TNT] Study)Benoit J Arsenault, Payal Kohli, Gilles Lambert, et al.
Cardiovascular Drugs and Therapy|November 24, 2011
Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trialStephen J Nicholls, Matthew A Cavender, John J P Kastelein, et al.
Circulation|July 1, 2004
Postmenopausal hormone therapy is associated with atherosclerosis progression in women with abnormal glucose toleranceBarbara V Howard, Judith Hsia, Pamela Ouyang, et al.
The American Journal of Cardiology|March 24, 2012
Comparison of lipid profiles and attainment of lipid goals in patients <65 years versus patients ≥65 years (from the Lipid Treatment Assessment Project [L-TAP] 2)Fatima Rodriguez, Raul D Santos, Michael Messig, et al.
Journal of the American College of Cardiology|December 11, 2012
Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetesDavid D Waters, Jennifer E Ho, S Matthijs Boekholdt, et al.
Pageof 16

Showing results (101-110 of 157) with videos related to

Sort By:
Pageof 16
Journal of the American Heart Association|January 24, 2018
Relationship of High-Density Lipoprotein Cholesterol With Renal Function in Patients Treated With AtorvastatinKwok Leung Ong, David D Waters, Rana Fayyad, et al.
Journal of the American College of Cardiology|January 31, 2015
Risk of new-onset diabetes and cardiovascular risk reduction from high-dose statin therapy in pre-diabetics and non-pre-diabetics: an analysis from TNT and IDEALPayal Kohli, David D Waters, Rita Nemr, et al.
Circulation|January 31, 2007
Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) studyKiran K Khush, David D Waters, Vera Bittner, et al.
Circulation|August 2, 2011
Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trialPhilip J Barter, Kerry-Anne Rye, Jean-Claude Tardif, et al.
Atherosclerosis|July 24, 2012
A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: the Lipid Treatment Assessment Project 2Raul D Santos, David D Waters, Lisa Tarasenko, et al.
The American Journal of Cardiology|June 23, 2016
Emerging Cardiovascular Disease Biomarkers and Incident Diabetes Mellitus Risk in Statin-Treated Patients With Coronary Artery Disease (from the Treating to New Targets [TNT] Study)Benoit J Arsenault, Payal Kohli, Gilles Lambert, et al.
Cardiovascular Drugs and Therapy|November 24, 2011
Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trialStephen J Nicholls, Matthew A Cavender, John J P Kastelein, et al.
Circulation|July 1, 2004
Postmenopausal hormone therapy is associated with atherosclerosis progression in women with abnormal glucose toleranceBarbara V Howard, Judith Hsia, Pamela Ouyang, et al.
The American Journal of Cardiology|March 24, 2012
Comparison of lipid profiles and attainment of lipid goals in patients <65 years versus patients ≥65 years (from the Lipid Treatment Assessment Project [L-TAP] 2)Fatima Rodriguez, Raul D Santos, Michael Messig, et al.
Journal of the American College of Cardiology|December 11, 2012
Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetesDavid D Waters, Jennifer E Ho, S Matthijs Boekholdt, et al.
Pageof 16